The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors – Yahoo Finance

Washington, DC, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announced the election of its 2022 Officers, Executive Committee, and Board of Directors.

The Executive Committee and Board of Directors oversee the formation and execution of ARMs strategic priorities and focus areas for the coming year.

ARM welcomes the diverse expertise and experience of our 2022 Board of Directors, said ARM Chief Executive Officer Janet Lambert. Our sector is poised to shape healthcare for years to come and our Board will be instrumental in advancing the delivery of transformative therapies for patients globally, while helping to eradicate barriers and legacy policy that could slow access.

ARM 2022 Officers:

Emile Nuwaysir, Ph.D. Chief Executive Officer, Ensoma (Chairman)Usman 'Oz' Azam, M.D. President and Chief Executive Officer, Tmunity Therapeutics (Vice Chairman)Amy Butler, Ph.D. President, Biosciences, Thermo Fisher Scientific (Secretary)Devyn Smith, Ph.D. Chief Executive Officer, Arbor Biotechnologies (Treasurer)

ARM 2022 Executive Committee:

Usman 'Oz' Azam, M.D. President and Chief Executive Officer, Tmunity TherapeuticsAmy Butler, Ph.D. President, Biosciences, Thermo Fisher ScientificMiguel Forte, M.D., Ph.D. Chief Executive Officer, Bone TherapeuticsClaudia Mitchell, MBA, Ph.D. Senior Vice President, Product and Portfolio Strategy, Astellas PharmaEmile Nuwaysir, Ph.D. Chief Executive Officer, EnsomaBob Smith, MBA Senior Vice President, Global Gene Therapy Business, PfizerDevyn Smith, Ph.D. Chief Executive Officer, Arbor BiotechnologiesArthur Tzianabos, Ph.D. President and Chief Executive Officer, Homology MedicinesChristopher Vann Senior Vice President and Chief Operating Officer, Autolus Therapeutics

Story continues

ARM 2022 Board of Directors* New to the Board for 2022

Usman 'Oz' Azam, M.D. President and Chief Executive Officer, Tmunity TherapeuticsMark Battaglini Senior Vice President, Global External Affairs & US Government Payer, bluebird bioAmy Butler, Ph.D. President, Biosciences, Thermo Fisher ScientificBradley Campbell, MBA President and Chief Operating Officer, Amicus TherapeuticsMiguel Forte, M.D., Ph.D. Chief Executive Officer, Bone TherapeuticsBobby Gaspar, M.D., Ph.D. Chief Executive Officer, Orchard TherapeuticsJerry Keybl, Ph.D. Senior Director, Cell & Gene Therapy, MilliporeSigmaBrett Kopelan Executive Director, Debra of AmericaDave Lennon, Ph.D. Former President, Novartis Gene TherapiesBruce Levine, Ph.D. Founding Director, Clinical Cell and Vaccine Production Facility, Abramson Cancer Center, University of Pennsylvania* Timothy Lu, M.D., Ph.D. Chief Executive Officer, Senti BiosciencesJohn Maslowski, M.S. Chief Commercial Officer, Forge Biologics* Chris Mason, M.D., Ph.D. Chief Scientific Officer, AVROBIO* Debra Miller Chief Executive Officer & Founder, CureDuchenneClaudia Mitchell, MBA, Ph.D. Senior Vice President, Product and Portfolio Strategy, Astellas Pharma* Alison Moore, Ph.D. Chief Technology Officer, Allogene TherapeuticsAdora Ndu, PharmD, J.D. Group Vice President, Worldwide Research & Development Strategy, Scientific Collaborations and Policy, BioMarinSusan Nichols President & Chief Executive Officer, Propel BioSciencesEmile Nuwaysir, Ph.D. Chief Executive Officer, EnsomaKarah Parschauer, J.D. Executive Vice President, General Counsel and Corporate Secretary, UltragenyxLouise Rodino-Klapac, Ph.D. Executive Vice President, Chief Scientific Officer, Sarepta TherapeuticsJeff Ross, Ph.D. Chief Executive Officer, Miromatrix Medical* Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer, Intellia TherapeuticsR.A. Session, MBA President, Founder & Chief Executive Officer, Taysha TherapeuticsCurran Simpson, M.S. Senior Vice President, Product Development and CTO, REGENXBIOSanjaya Singh, Ph.D. Vice President & Global Head, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & DevelopmentBob Smith, MBA Senior Vice President, Global Gene Therapy, PfizerDevyn Smith, Ph.D. Chief Executive Officer, Arbor BiotechnologiesJoseph Tarnowski, Ph.D. Senior Vice President of Cell and Gene Therapy Platforms, Medicinal Science & Technology, R&DArthur Tzianabos, Ph.D. President and Chief Executive Officer, Homology MedicinesChristopher Vann Senior Vice President and Chief Operating Officer, Autolus TherapeuticsKristin Yarema, Ph.D. Chief Commercial Officer, Atara Biotherapeutics

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 12-year history, ARM has become the voice of the sector, representing the interests of 400+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Kaitlyn Dupont8037278346kdupont@alliancerm.org

View post:
The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors - Yahoo Finance